Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Coformation of Vibostolimab (MK-7684) with Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants with Selected Solid Tumors

Next Previous
Trial Profile

A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Coformation of Vibostolimab (MK-7684) with Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants with Selected Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Fluorouracil (Primary) ; Lenvatinib (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary) ; Pembrolizumab+vibostolimab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Biliary cancer; Carcinoma; Cervical cancer; Cholangiocarcinoma; Endometrial cancer; Gallbladder cancer; Gastric cancer; Head and neck cancer; Liver cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms KEYVIBE-005
  • Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.; MSD KK

Most Recent Events

  • 23 May 2025 Planned End Date changed from 12 Aug 2026 to 15 Aug 2025.
  • 23 May 2025 Planned primary completion date changed from 12 Aug 2026 to 15 Aug 2025.
  • 15 Oct 2024 Planned number of patients changed from 610 to 604.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top